Myron Arlen

Title: Myron Arlen: Innovator in Monoclonal Antibody Research

Introduction

Myron Arlen is a distinguished inventor based in Great Neck, NY (US), known for his significant contributions to the field of monoclonal antibody research. With a total of 14 patents to his name, Arlen has made remarkable advancements in the treatment of cancers, particularly colorectal and pancreatic cancers.

Latest Patents

Among his latest patents, Arlen has developed recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers. This invention provides purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA). It also includes nucleic acid sequences encoding the antibody chains and the amino acid sequences corresponding to these nucleic acids, along with various uses for these sequences. Another notable patent focuses on monoclonal antibody therapy for pancreatic cancer, which relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions, as well as antibody fragments and competitively binding antibodies in the treatment of pancreatic cancer.

Career Highlights

Throughout his career, Myron Arlen has worked with several prominent companies, including Precision Biologics, Inc. and International Bioimmune Systems, Inc. His work has been pivotal in advancing therapeutic options for cancer patients, showcasing his dedication to medical innovation.

Collaborations

Arlen has collaborated with notable colleagues in the field, including Kwong Y Tsang and J Andrew Bristol. These partnerships have further enhanced his research and development efforts in monoclonal antibody therapies.

Conclusion

Myron Arlen's contributions to the field of monoclonal antibodies have had a profound impact on cancer treatment. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.